Catheter Ablation of Atrial Fibrillation and Risk of Asymptomatic Cerebral Embolism

Recent studies have suggested that a significant minority of patients undergoing atrial fibrillation catheter ablation (AFCA) develop evidence of acute, asymptomatic cerebral emboli (ACE) detected by brain magnetic resonance imaging. Although the prognostic significance of ACE associated with AFCA remains unclear, given the heightened risk of dementia associated with asymptomatic chronic infarcts on brain imaging, it is imperative to understand the pathogenesis of ACE and identify methods to mitigate the risk of emboli associated with AF ablation. In this paper, we review the incidence of ACE associated with AFCA and discuss patient‐ and procedure‐specific markers of risk for asymptomatic embolism. We also review the data to support strategies, which have been proposed to reduce the incidence of ACE.     

Incidence and Prevention of Cardiac Tamponade Complicating Ablation for Atrial Fibrillation

Cardiac tamponade complicating catheter ablation of atrial fibrillation (AF) occurs in approximately 1% of pulmonary vein isolation (PVI), and up to 6% of linear ablation procedures. We reviewed 348 consecutive AF ablation (including repeat) procedures over 1 year, which all included PVI, with additional linear lesions at the mitral isthmus in 73%, and cavotricuspid isthmus (CTI) in 76%. An irrigated-tip ablation catheter was used, with power limited to 25–35 W for PVI and 45–60 W for linear lesions. Tamponade occurred in seven men and three women (2.9% of the population) during the creation of linear ablation lesions. Mechanical perforations occurred in two patients, and "popping" during radiofrequency (RF) energy delivery at the mitral isthmus in six, and at the CTI in two patients. Peak RF power was significantly higher in patients with than without tamponade (53 ± 4 W vs 48 ± 7 W; P = 0.02), and was greater than 48 W in all cases of "popping." In the following year, RF power for linear ablation was limited to ≤42 W. Among 398 procedures, tamponade occurred in four patients (1.0%; P = 0.047 vs first year), three from "popping" and one from mechanical trauma. Procedural success rate remained the same despite reduction of power. Risk of tamponade was highest during linear ablation, mainly associated with high energy delivery and "popping." Reducing the energy limited, though did not eliminate this complication.     

Catheter Ablation for Paroxysmal Atrial Fibrillation: A Randomized Comparison between Multielectrode Catheter and Point‐by‐Point Ablation

Introduction: Catheter ablation for paroxysmal atrial fibrillation is widely used for patients with drug‐refractory paroxysms of arrhythmia. Recently, novel technologies have been introduced to the market that aim to simplify and shorten the procedure. Aim: To compare the clinical outcome of pulmonary vein (PV) isolation using a multipolar circular ablation catheter (PVAC group), with point‐by‐point PV isolation using an irrigated‐tip ablation catheter and the CARTO mapping system (CARTO group; CARTO, Biosense Webster, Diamond Bar, CA, USA). Methods: Patients with documented PAF were randomized to undergo PV isolation using PVAC or CARTO. Atrial fibrillation (AF) recurrences were documented by serial 7‐day Holter monitoring. Results: One hundred and two patients (mean age 58 ± 11 years, 68 men) were included in the study. The patients had comparable baseline clinical characteristics, including left atrial dimensions and left ventricular ejection fraction, in both study arms (PVAC: n = 51 and CARTO: n = 51). Total procedural and fluoroscopic times were significantly shorter in the PVAC group (107 ± 31 minutes vs 208 ± 46 minutes, P < 0.0001 and 16 ± 5 minutes vs 28 ± 8 minutes, P < 0.0001, respectively). The AF recurrence was documented in 23% and 29% of patients in the PVAC and CARTO groups, respectively (P = 0.8), during the mean follow‐up of 200 ± 13 days. No serious complications were noted in both study groups. Conclusions: Clinical success rates of PV isolation are similar when using multipolar circular PV ablation catheter and point‐by‐point ablation with a three‐dimensional (3D) navigation system in patients with PAF, and results in shorter procedural and fluoroscopic times with a comparable safety profile. (PACE 2010; 33:1039–1046)     

Antiarrhythmic Drug Therapy after Radiofrequency Catheter Ablation in Patients with Atrial Fibrillation

Objectives: The use of antiarrhythmic drugs after ablation is a controversial issue when evaluating the efficacy of atrial fibrillation (AF) ablation. This study compares in a prospective and randomized fashion the impact of an antiarrhythmic drug in preventing AF recurrence after AF ablation.
Methods: From February 2004 to May 2005, 107 consecutive patients (mean age 57 ± 10 years, 69 men), with paroxysmal (60%) or persistent (40%) drug refractory AF, were randomly assigned to ablation alone (Group A, 53 patients) or combined with the best antiarrhythmic therapy, preferably amiodarone (Group B, 54 patients). All patients underwent cavo-tricuspid and left inferior pulmonary vein (PV)-mitral isthmus ablation plus circumferential PV ablation, using a guided electro-anatomical approach. Standard electrocardiograms (ECG), and ambulatory and transtelephonic ECG monitoring were used to assess AF recurrences. Recurrences during the first month after ablation were excluded from this analysis.
Results: At 12 months of follow-up, no significant difference was observed in the rates of AF recurrences between Group A (18/53 patients, 34%) and Group B (16/54 patients, 30%). The percentage of patients with ≥1 asymptomatic AF episode was higher in Group B than in Group A (10/16 patients, 63%, vs 5/18 patients, 28%, P = 0.04).
Conclusions: Continuing antiarrhythmic drug therapy in patients who undergo catheter ablation for AF did not lower the rate of AF recurrences. Antiarrhythmic drugs increased the proportion of patients with asymptomatic AF episodes.     

Anatomy-Guided Linear Atrial Lesions for Radiofrequency Catheter Ablation of Atrial Fibrillation

The surgical atrial maze procedure has provided proof that atrial fibrillation can be cured by performing atrial incisions based on anatomical and electrophysiological principles. Preliminary reports of attempts at radio frequency catheter ablation of atrial fibrillation utilizing an anatomy-based "linear incision" method have shown the feasibility of the method. However, postprocedural atrial fibrillation recurrence has been common and in addition new, uniform tachycardias have developed in some patients. Both of these outcomes may be in part due to incomplete or inconsistent lesion deployment. This article details the use of the CARTO system for deploying anatomy guided linear atrial lesions for the purpose of curing atrial fibrillation. The procedure is comprised of three phases, which are discussed in detail: (1) baseline map: (2) lesion deployment and; (3) lesion assessment. Using a single standard ablation electrode, lesions can be deployed safely, and complete lesions can be confirmed. Paradigms for right and left atrial incisions are proposed.     

Cost Analysis of Catheter Ablation for Paroxysmal Atrial Fibrillation

WEERASOORIYA, R., et al. : Cost Analysis of Catheter Ablation for Paroxysmal Atrial Fibrillation . RF ablation for paroxysmal atrial fibrillation (PAF) is a curative treatment, which when successful, eliminates the need to take antiarrhythmic drugs, be anticoagulated, and have recurrent physician visits or hospital admissions. The authors performed a retrospective cost comparison of RF ablation versus drug therapy for PAF. The study population consisted of 118 consecutive patients with symptomatic, drug refractory PAF who underwent   1.52 ± 0.71   RF ablation procedures (range 1–4) for PAF. During a follow-up of 32 ± 15 weeks, 85 (72%) patients remained free of clinical recurrence in absence of antiarrhythmic drugs. The cost of RF ablation was calculated in the year 2001 euros on the basis of resource use. The mean cost of pharmacologic treatment prior to ablation was 1,590 euros/patient per year. The initial cost of RF ablation for PAF was 4,715 euros, then 445 euros/year. After 5 years, the cost of RF ablation was below that of ongoing medical management, and continued to diverge thereafter. RF catheter ablation may be a cost-effective alternative to long-term drug therapy in patients with symptomatic, drug refractory PAF. (PACE 2003; 26[Pt. II]:292–294)     

经导管射频消融治疗阵发性心房颤动临床研究

[目的]探讨经导管射频消融治疗阵发性心房颤动的有效性与安全性.[方法]60例阵发性心房颤动患者药物治疗无效且反复发作,采用节段性消融肺静脉电隔离术、CARTO和EnSite 3000三维空间标测系统指导下肺静脉电隔离术3种不同的方法进行肺静脉电位经导管射频消融隔离治疗,术后随访3～41个月.[结果]60例患者中42例(70.0%)经消融成功,10例(16.7%)有效,8例(13.3%)失败,无严重并发症;CARTO和EnSite 3000三维空间标测系统指导肺静脉电隔离术可明显减少X线曝光时间.[结论]经导管射频消融治疗局灶性心房颤动是可行的,对大部分患者是有效的.     

Contemporary Challenges of Catheter Ablation for Atrial Fibrillation

Purpose

Catheter ablation of atrial fibrillation (AF) is now one of the most frequently performed ablation procedures, but there are currently 2 important challenges: achieving permanent/durable rather than transient pulmonary vein isolation (PVI) and improving the results of ablation for the wider patient population with persistent AF.

Methods

Recent technical advances in the technique of ablation and the results of clinical trials aimed at achieving more permanent and durable PVI are reviewed. We also summarize recent advances in identifying atrial fibrosis and in understanding the pathophysiology of AF relevant to selecting patients for ablation of persistent AF.

Findings

The use of contact force–sensing technology, adenosine testing after ablation, and pace capture–guided ablation all have the potential for achieving more durable ablation. Selection of patients suitable for ablation of persistent AF may be improved by assessing the extent of atrial fibrosis with delayed enhancement imaging with cardiac magnetic resonance or by assessing the pattern of atrial electrical activity with the use of complex atrial electrograms. Advances in treatment are likely to result from the recognition of localized rotors and focal sources as primary sustaining mechanisms for all types of human AF and in the use of noninvasive mapping for their identification. Linear ablation to supplement PVI may improve the results of AF ablation.

Implications

Rapidly unfolding advances in the techniques of AF ablation and the understanding of mechanisms of AF hold promise for improving the durability of PVI and for extending the technique to carefully selected patients with persistent AF.     

Catheter Ablation for Atrial Fibrillation

Atrial fibrillation (AF) is the most common arrhythmia in adults, and its prevalence is on the rise. Catheter ablation of AF, once considered a novel procedure, has become the most commonly performed technique for treating patients with severe symptomatic AF. This article reviews the latest American Heart Association/American College of Cardiology/Heart Rhythm Society guideline on the indications for AF and summarizes techniques available to achieve freedom of recurrent arrhythmia and relief from symptoms. Nurse practitioners need to provide guideline-directed care before, during, and after catheter ablation to improve patients’ quality of life and prevent complications.     

Internal Atrial Defibrillation During Electrophysiological Studies and Focal Atrial Fibrillation Ablation Procedures

Induction of sustained AF during electrophysiological studies requires electrical cardioversion to restore sinus rhythm for continuation of the electrophysiological study and mapping procedure. The study included 104 consecutive patients (age 59 +/- 12 years, 74 men), who were in stable sinus rhythm at the beginning of the electrophysiological study, underwent internal atrial defibrillation (IAD) of AF (> 15 minutes) that was induced during electrophysiological study. In 21 patients, AF was regarded to be the clinical problem (group I), and in the remaining 83 patients other arrhythmias represented the primary target of the electrophysiological study (group II). A 7.5 Fr cardioversion catheter (EP Medical) equipped with a distal array was used and placed in the left pulmonary artery and a proximal array of the same size was located along the lateral right atrial wall. All patients were successfully cardioverted with a mean energy of 6.2 +/- 4.0 1. In 18 (78%) of 21 group I patients and in 12 (14%) of 81 group II patients, AF recurred 3.7 +/- 3.4 and 2.4 +/- 1.4 times during electrophysiological study, respectively. The IAD shock did not suppress focal activity, thus the mapping of atrial foci responsible for AF could be continued even after several IADs. No IAD related complications occurred during the study. In conclusion, (1) IAD can be safely and successfully performed during electrophysiological study without using narcotic drugs or high electric energies; (2) IAD does not suppress focal activity; and (3) even if AF recurs frequently during the electrophysiological study, IAD can be performed several times without significant time delay.     

Symptomatic and Asymptomatic Atrial Fibrillation after Pulmonary Vein Ablation and the Impact on Quality of Life

Background: The aim of this prospective study was to evaluate the recurrences of atrial fibrillation (AF) and flutter (AFL) after circumferential pulmonary vein ablation (CPVA) using repetitive long-term Holter recordings, and to evaluate the change in quality of life (QoL), especially in patients with asymptomatic AF recurrences.
Methods: A total of 149 patients with AF were followed up with 7-day Holter monitoring at 3, 6, and 12 months after CPVA. We calculated the burden of AF/AFL defined as the percentage of time in AF/AFL, and patients with documented arrhythmia were divided into isolated symptomatic episodes of arrhythmia, mixed symptomatic/asymptomatic arrhythmia, or isolated asymptomatic arrhythmia. The QoL was analyzed with SF-36 questionnaires in patients with sinus rhythm after CPVA, and in patients with recurrence of symptomatic and asymptomatic arrhythmia, respectively.
Results: Asymptomatic arrhythmia was observed in 44% of the patients with documented arrhythmia at 12 months of follow-up. In patients with persistent AF, 63% of the documented arrhythmia at 12 months of follow-up was asymptomatic and often persistent. In the subgroup of patients with asymptomatic arrhythmia, the QoL improved significantly in the physical scores, in contrast to patients with symptomatic arrhythmia who had unchanged or worsened QoL scores.
Conclusions: Asymptomatic arrhythmia is very common after AF ablation. Our data indicate that these patients improve their physical component of the QoL significantly, which may be considered a palliative success of treatment. We suggest that patients with asymptomatic AF recurrences are carefully evaluated before considering reablation. Repetitive rhythm monitoring after AF ablation is very important considering the postablation management of anticoagulant therapy.     

P波离散度预测阵发性心房颤动射频消融术后复发的价值

【目的】探讨阵发性房颤射频消融术后复发的预测因素。【方法】145例行环肺静脉导管射频消融术的阵发性房颤患者,记录术前及术后心电图,测量最大、最小P波时限,计算P波离散度。【结果】术后平均随访（6．1±0．2）个月,根据是否复发房颤分为复发组51例和未复发组94例。复发组较未复发组的术前最大P渡时限增大[（120．2±11．0）ms比（105．6±7．8）ms,P〈0．001];P波离散度明显增大[（53．6±6．2）ms比（39．9±4．7）ms,P〈0．001];两组P波最小时限及其他临床指标均无统计学差异。多因素分析示术前P波离散度≥46ms（P=0．04）和发作频率≥5次／月（P=0．01）是房颤复发的预测因素,二者预测复发的灵敏度分别是87％和86％;特异度92％和85％。【结论】术前P波离散度及房颤发作频率一定程度上可预测阵发性房颤射频消融术后的复发。